---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-003717"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T04:47:33.818960+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biodesix reports FY2024 revenue $71.3M (+45% YoY), exceeds guidance midpoint

## Summary
- Total revenue $71.3M in FY2024, up 45% YoY; Q4 revenue $20.4M, up 39% YoY.
- Lung Diagnostic revenue $64.7M (+43% YoY); test volumes 54,300 (+40% YoY).
- Biopharma Services revenue $6.6M (+69% YoY); $12.2M contracted backlog for 2025 (+54%).
- Cash and equivalents $26.2M as of Dec 31, 2024.
- Results are preliminary and unaudited; Q4 and FY2024 figures subject to final audit.

## SEC filing metadata
- accession: 0000950170-25-003717
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017025003717/0000950170-25-003717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017025003717/bdsx-20250110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-003717
- JSON: https://secwatch.observer/filing/0000950170-25-003717.json
- Plain text: https://secwatch.observer/filing/0000950170-25-003717.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.